DIF-3
Based on 8 publication(s) in Google Scholar
DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.84%
- CAS No.: 113411-17-9
- 화학식: C13H17ClO4
- 분자량:272.72
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Kinase Inhibitor Library
HY-L009
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Antihypertensive Compound Library
HY-L145
-
Metabolic Enzyme Compound Library
HY-L146
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Posttranslational Modification Library
HY-L226
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) DIF-3
More- J Transl Med. 2026 Feb 9;24(1):361. [Abstract]
- Oncogene. 2023 Nov;42(47):3503-3513. [Abstract]
- Mol Med. 2024 Dec 20;30(1):260. [Abstract]
- Int J Oncol. 2026 Jan;68(1):8. [Abstract]
- mBio. 2025 Sep 25:e0037325. [Abstract]
- Diabetol Metab Syndr. 2025 Jun 5;17(1):193. [Abstract]
- Placenta. 2025 Oct 7:171:194-204. [Abstract]
- bioRxiv. 2025 Feb 8:2025.02.07.637189. [Abstract]
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2 μM
Compound: DIF-3
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 28814374] |
| S2 | IC50 |
4.6 μM
Compound: 2, DIF-3
|
Immunosuppressive activity in Drosophila S2 cells expressing att-luc reporter gene assessed as inhibition of peptidoglycan-induced attacin production pre-treated for 1.5 hrs before peptidoglycan stimulation for 8 hrs by luciferase reporter gene assay
Immunosuppressive activity in Drosophila S2 cells expressing att-luc reporter gene assessed as inhibition of peptidoglycan-induced attacin production pre-treated for 1.5 hrs before peptidoglycan stimulation for 8 hrs by luciferase reporter gene assay
|
[PMID: 26122773] |
DIF-3 (10-30 μM, 24-48 h) inhibits proliferation in a dose-dependent manner in human colon cancer cells[1].
DIF-3 (30 μM, 24 h) arrests the cell cycle at G0/G1 phase in human colon cancer cells[1].
DIF-3 (10-30 μM, 1-24 h) induces proteolysis of cyclin D1 and c-Myc in human colon cancer cells via activation of GSK-3β[1].
DIF-3 (10-30 μM, 1-24 h) inhibits Wnt/β-catenin signaling pathway-related proteins in human colon cancer cells[1].
DIF-3 (10 μM, 4 h) inhibits lysophosphatidic acide (LPA) stimulated migration of murine osteosarcoma LM8 cells[2].
DIF-3 (20 μM, 0.25-24 h) inhibits mTOR signaling and induces autophagy in K562 CML cells[3].
DIF-3 (20 μM) induces mitochondrial membrane potential (MMP) (0-10 min), a decrease of ATP content (6 h) and an induction of ROS production (0-30 min) in K562 cells[3].
DIF-3 (10 μM, 3 d) suppresses the growth of Trypanosoma. cruzi in HT1080 cells with an IC50 of 3.95 μM[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT-116, DLD-1
-
Concentration:10, 20, 30 μM
-
Incubation Time:24, 48 h
-
Result:Strongly inhibited proliferation in a dose-dependent manner in both cell lines.
HCT-116 cells were more sensitive to DIF-3 than DLD-1 cells.
-
Cell Line:HCT-116, DLD-1
-
Concentration:30 μM
-
Incubation Time:24 h
-
Result:Significantly increased the number of cells in G0/G1 phase and decreased those in S phase in both cell lines.
Also significantly increased the number of cells in G2 phase when HCT-116 cells were employed, this effect was not observed by using DLD-1 cells.
-
Cell Line:LM8
-
Concentration:10 μM
-
Incubation Time:4 h
-
Result:Suppressed LPA-induced cell migration, whereas did not significantly affected cell migration in the absence of LPA.
-
Cell Line:K562
-
Concentration:20 μM
-
Incubation Time:0.25, 0.5, 1, 3, 6, 24 h for mTOR study; 6, 16, 36, 48 h for Cathepsin B activity study
-
Result:Induced the rapid dephosphorylation of mTOR at Ser2481. Inhibited the mTOR pathway and leads to a rapid and robust conversion of LC3-I to LC3-II.
Increased autophagy was accompanied by the late activation of cathepsin B.
-
Cell Line:HCT-116
-
Concentration:10, 20, 30 μM
-
Incubation Time:1, 3, 6, 12, 24 h
-
Result:Induced a rapid and marked reduction in the amount of cyclin D1 protein and c-Myc protein in a time and dose-dependent manner.
Had no effect on the expression level of β-catenin (30 μM for 24 h).
Reduced the amount of TCF7L2 which increased gradually over time in control cells, in a time and dose-dependent manner.
Reduction of TCF7L2 was associated with the transcriptional inhibition of cyclin D1 mRNA in HCT-116 cells.
-
Cell Line:HCT-116
-
Concentration:30 μM
-
Incubation Time:1 h
-
Result:Effects could be attenuated by MG132 (HY-13259) and SB216763 (HY-12012), indicating the involvement of GSK-3β in degradation of cyclin D1 and c-Myc.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mutyh-/- mice (KBrO3 dissolved in water at a concentration of 2 g/L was administered to 4-week-old mice for 12 weeks)[1]
-
Dosage:150 mg/kg
-
Administration:Oral gavage (p.o.); once a day for 5 days/week over 4 weeks
-
Result:Markedly reduced the number of intestinal tumors, especially the number of large tumors with a diameter of >2.0 mm.
No differences in the appearance, activity, body weight, or blood cell counts.
The numbers of TCF7L2-and cyclin D1-positive nuclei in tumors were significantly decreased.
Chemical Information
-
CAS No. 113411-17-9
-
Appearance Solid
-
분자량 272.72
-
화학식 C13H17ClO4
-
Color White to off-white
-
SMILES
O=C(CCCCC)C1=C(C=C(C(Cl)=C1O)OC)O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
J Transl Med
MaR1 and NGF combine to inhibit autophagy through the GSK-3β/β-catenin pathway to promote sciatic nerve repair. [Abstract]2026 Feb 9;24(1):361. PMID: 41664203 -
Oncogene
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC. [Abstract]2023 Nov;42(47):3503-3513. PMID: 37845392 -
Mol Med
CGREF1 modulates osteosarcoma proliferation by regulating the cell cycle through the Wnt/β-catenin signaling pathway. [Abstract]2024 Dec 20;30(1):260. PMID: 39707194 -
Int J Oncol
Ephrin‑B2 promotes gastric cancer growth by inhibiting apoptosis and regulating the cell cycle via the Wnt/β‑catenin signaling pathway. [Abstract]2026 Jan;68(1):8. PMID: 41268595 -
mBio
The Streptococcus pyogenes Rgg2/Rgg3 quorum sensing system causes global suppression of macrophage inflammatory programs via an intranuclear mechanism. [Abstract]2025 Sep 25:e0037325. PMID: 40996031 -
Diabetol Metab Syndr
IL-37 inhibited inflammation to improve gestational diabetes mellitus through the GSK3/NF-κB pathway. [Abstract]2025 Jun 5;17(1):193. PMID: 40474280 -
Placenta
The downregulation of B2R inhibits spiral artery remodeling by reducing the autophagy of trophoblast cells. [Abstract]2025 Oct 7:171:194-204. PMID: 41076744 -
bioRxiv
Suppressed macrophage response to quorum-sensing-active Streptococcus pyogenes occurs at the level of the nucleus. [Abstract]2025 Feb 8:2025.02.07.637189. PMID: 39975246
용액&용해도
DMSO : 100 mg/mL (366.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Naoya Kubokura , et al. Differentiation-inducing factor-3 inhibits intestinal tumor growth in vitro and in vivo. J Pharmacol Sci. 2015 Apr;127(4):446-55. [Content Brief]
[2]. Kubohara Y, et al. Derivatives of Dictyostelium differentiation-inducing factors inhibit lysophosphatidic acid-stimulated migration of murine osteosarcoma LM8 cells. Biochem Biophys Res Commun. 2015 Aug 7;463(4):800-5. [Content Brief]
[3]. Dubois A, et al. Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death. Oncotarget. 2016 May 3;7(18):26120-36. [Content Brief]
[4]. Nakajima-Shimada J, et al. Derivatives of Dictyostelium discoideum differentiation-inducing factor-3 suppress the activities of Trypanosoma cruzi in vitro and in vivo. Biochem Pharmacol. 2013 Jun 1;85(11):1603-10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6668 mL | 18.3338 mL | 36.6676 mL | 91.6691 mL |
| 5 mM | 0.7334 mL | 3.6668 mL | 7.3335 mL | 18.3338 mL | |
| 10 mM | 0.3667 mL | 1.8334 mL | 3.6668 mL | 9.1669 mL | |
| 15 mM | 0.2445 mL | 1.2223 mL | 2.4445 mL | 6.1113 mL | |
| 20 mM | 0.1833 mL | 0.9167 mL | 1.8334 mL | 4.5835 mL | |
| 25 mM | 0.1467 mL | 0.7334 mL | 1.4667 mL | 3.6668 mL | |
| 30 mM | 0.1222 mL | 0.6111 mL | 1.2223 mL | 3.0556 mL | |
| 40 mM | 0.0917 mL | 0.4583 mL | 0.9167 mL | 2.2917 mL | |
| 50 mM | 0.0733 mL | 0.3667 mL | 0.7334 mL | 1.8334 mL | |
| 60 mM | 0.0611 mL | 0.3056 mL | 0.6111 mL | 1.5278 mL | |
| 80 mM | 0.0458 mL | 0.2292 mL | 0.4583 mL | 1.1459 mL | |
| 100 mM | 0.0367 mL | 0.1833 mL | 0.3667 mL | 0.9167 mL |
Powered by Bioz